rss
Br J Ophthalmol 90:1542-1547 doi:10.1136/bjo.2006.098426
  • Perspective

Vascular endothelial growth factor biology: clinical implications for ocular treatments

  1. R B Bhisitkul
  1. Correspondence to: R B Bhisitkul Department of Ophthalmology, Beckman Vision Center, University of California San Francisco, 10 Koret Way, K301, San Francisco, CA 94143, USA; BhisitkulR{at}vision.ucsf.edu
  • Accepted 19 June 2006

Abstract

Decades of research on vascular endothelial growth factor (VEGF) have reached fruition with the recent development of intravitreal anti-VEGF treatments for exudative age-related macular degeneration. VEGF is a critical regulator of angiogenesis and vascular permeability with diverse roles, both pathological and physiological, during development and adulthood. The aim of this article is to review aspects of VEGF biology that may be relevant to the clinical use of anti-VEGF agents in ophthalmology: molecular characteristics and isoforms of VEGF; its roles in vasculogenesis, vascular maintenance and angiogenesis; systemic effects of VEGF inhibition; and properties of current anti-VEGF agents.

Footnotes

  • Competing interests: None declared.

Register for free content


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article